<a href="https://laohu8.com/S/MLTX">MoonLake Immunotherapeutics</a> Faces Securities Fraud Class Action
A class action lawsuit has been filed against Moonlake Immunotherapeutics on behalf of investors who suffered losses between March 10, 2024 and September 29, 2025. The complaint alleges that the company made false statements and concealed key information regarding its sole drug candidate, SLK. Specifically, it is claimed that SLK and BIMZELX share the same molecular targets, and that SLK's unique Nanobody structure would not deliver superior clinical benefits or efficacy compared to the traditional monoclonal structure of BIMZELX. The lawsuit contends that Moonlake Immunotherapeutics lacked a reasonable basis for its positive statements about SLK's superiority over monoclonal antibodies. The legal action seeks to recover damages for affected investors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1117417) on December 15, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。